Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia.

Autor: Lin CC; Methodist Neurological Institute, Houston, TX, USA., Ondo WG; Methodist Neurological Institute, Houston, TX, USA; Weill Cornell Medical School, New York, NY, USA. Electronic address: wondo@houstonmethodist.org.
Jazyk: angličtina
Zdroj: Journal of the neurological sciences [J Neurol Sci] 2018 Jun 15; Vol. 389, pp. 48-54. Date of Electronic Publication: 2018 Feb 05.
DOI: 10.1016/j.jns.2018.02.014
Abstrakt: Although VMAT2-inhibitors are now established as first-line treatment for tardive dyskinesia, not all patients respond to, or tolerate them. Numerous other agents have been adopted to treat tardive dyskinesia, but with variable results and generally lower quality methodologic reports. Amantadine is the most promising but benzodiazepines, branched chain neutral amino acids, Vitamin B6, several nutraceuticals, and botulinum toxin injections might help some patients. In all cases, better placebo controlled trials are needed before definitive recommendations can be made.
(Copyright © 2018 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: